Mpox
Mpox is a zoonotic and human-to-human viral disease caused by monkeypox virus (Orthopoxvirus monkeypox), an enveloped double-stranded DNA virus in the family Poxviridae that produces vesiculopustular skin and mucosal lesions alongside systemic lymphadenopathy.
Mpox (formerly designated monkeypox until the World Health Organization updated the disease nomenclature in November 2022) is an acute viral infectious disease caused by monkeypox virus (MPXV, taxonomic species Orthopoxvirus monkeypox), a brick-shaped, enveloped double-stranded DNA virus in the genus Orthopoxvirus, family Poxviridae. Closely related to variola virus (the eradicated causative agent of smallpox), vaccinia virus, and cowpox virus, MPXV was first isolated in 1958 from vesiculopustular lesions in captive cynomolgus macaques (Macaca fascicularis) in Copenhagen, Denmark, and was first recognized as a human pathogen in 1970 in a nine-month-old infant in the Democratic Republic of the Congo (DRC) short after smallpox eradication campaigns ceased routine Orthopoxvirus vaccination. Endemic in tropical rainforests of Central and West Africa—where arboreal rodents including rope squirrels (Funisciurus), sun squirrels (Heliosciurus), and African giant pouched rats (Cricetomys) act as putative reservoir hosts—MPXV has diverged into two major phylogenetic clades (Clade I and Clade II) that execute sustained human-to-human transmission via direct cutaneous, mucosal, and sexual contact.
Virion Architecture, Cytoplasmic Replication, and Clade Phylogenetics
Brick-Shaped Virion Forms and Linear Hairpin Genome
Like all poxviruses, MPXV virions are large pleomorphic brick- or ovoid-shaped particles (~200–250 nm wide by ~250–300 nm long) resolved by cryo-electron tomography into a biconcave dumbbell-shaped nucleoprotein core flanked by two proteinaceous lateral bodies and enclosed by a corrugated lipoprotein outer membrane studded with surface tubules. During infection, the virus produces two antigenically distinct infectious morphotypes that serve complementary roles in pathogenesis:
- Intracellular Mature Virion (IMV, or Mature Virion, MV): Assembled inside cytoplasmic viral factories and surrounded by a single lipoprotein membrane containing surface proteins such as A27, H3, D8, and L1. Stable in the external environment, IMVs are released primarily upon host cell lysis and mediate inter-host transmission via fomites and epidermal scabs.
- Extracellular Enveloped Virion (EEV, or Wrapped Virion, WV): Formed when a subset of IMVs is wrapped by a double membrane derived from the trans-Golgi network or early endosomes and exocytosed across the plasma membrane, leaving an outer envelope bearing host complement-regulatory proteins and six EEV-specific viral glycoproteins (including A33, A34, A56, and B5, the homolog of variola B6R). Because the EEV outer lipid envelope shields internal IMV antigens from neutralizing antibodies, EEVs drive rapid cell-to-cell actin-tail propulsion and systemic hematogenous dissemination within the infected host.
The MPXV genome is a linear double-stranded DNA molecule of ~196.8 to 197.2 kilobase pairs (kbp) (~33% G+C content) encoding approximately 190 non-overlapping open reading frames (ORFs). At both physical termini, the sense and antisense DNA strands are covalently joined by AT-rich hairpins and flanked by Inverted Terminal Repeats (ITRs, ~6.4–10 kbp) containing tandem repeats and virulence genes. Whereas the central ~102 kbp core region (ORFs C10L to A25R) is conserved across Orthopoxvirus species and encodes essential transcription, DNA replication, and virion assembly machinery, the variable terminal regions encode host-range factors and immunomodulatory proteins that antagonize host interferons, tumor necrosis factor (TNF) receptors, interleukin-1β, and complement cascades.
Exclusive Cytoplasmic Replication Factory
Uniquely among animal DNA viruses, MPXV replicates entirely within the host cell cytoplasm inside perinuclear membrane-bounded compartments called viral factories (historically termed Guarnieri bodies). Because the virion does not enter the host nucleus, the incoming viral core must package its own multisubunit DNA-dependent RNA polymerase, mRNA capping enzyme, and poly(A) polymerase to initiate early transcription immediately upon uncoating. Early viral proteins uncoat the inner core, suppress cytosolic DNA sensing via the cGAS–STING pathway, and assemble the viral DNA replication holoenzyme—comprising the catalytic DNA polymerase E9L (OPG071), the processivity heterodimer A20R/D4R (uracil-DNA glycosylase), the primase-helicase D5R, and the single-stranded DNA-binding protein I3L—which replicates the genome through a self-priming nicking and strand-displacement concatemeric mechanism before activating intermediate and late structural gene transcription.
| Clade / Subclade | Geographic Origin & Primary Distribution | Historical Case Fatality Ratio (CFR) | Key Genomic & Transmission Characteristics |
|---|---|---|---|
| Clade Ia (formerly Central African Clade) | Congo Basin (DRC, Central African Republic, Republic of the Congo, Gabon, South Sudan) | 3%–10% (higher in unvaccinated children <15 yr) | Intact complement-control protein (C3L / MOPICE) and IL-1β binding protein; zoonotic spillover + household spread |
| Clade Ib | Eastern DRC (South Kivu, 2023–2024), Burundi, Uganda, Rwanda, Kenya, and international travel cases | ~0.5%–3.5% (varies by age and obstetric/HIV status) | ~1.1 kbp deletion in OPG032 (C3L) + enriched APOBEC3 TC→TT/GA→AA mutations; sustained heterosexual & household spread |
| Clade IIa (formerly West African Clade) | West Africa (Nigeria, Côte d'Ivoire, Liberia, Sierra Leone, Ghana; 2003 US prairie dog outbreak) | <1%–3% | Deletion of C3L (MOPICE) and fragmentation of B21R-like ORFs; primarily zoonotic with limited secondary chains |
| Clade IIb (Lineages A and B.1) | Nigeria (2017–present) and global multi-country outbreak (>100,000 cases across >120 countries, 2022–2026) | ~0.1%–0.3% globally (higher in advanced HIV with CD4 <100 cells/μL) | Accelerated APOBEC3F/G cytidine deamination (~6–12× baseline substitution rate); dense sexual network transmission |
Clinical Course, APOBEC3 Mutational Signatures, and Countermeasures
Biphasic Illness, Centrifugal Rash, and Mucosal Presentations
Following percutaneous, mucosal, or respiratory inoculation, mpox exhibits an incubation period averaging 6 to 13 days (range 5 to 21 days) before progressing through two clinical phases:
- Invasion / Prodromal Phase (Days 0 to 5): Characterized by fever, intense headache, myalgia, backache, asthenia, and prominent maxillary, cervical, or inguinal lymphadenopathy (lymph node swelling of 1 to 4 cm)—a key clinical feature distinguishing mpox from smallpox and varicella (chickenpox).
- Eruptive Cutaneous and Mucosal Phase (2 to 4 Weeks): Within 1 to 3 days of fever onset, an exanthem erupts, classically in a centrifugal distribution concentrated on the face, palms of the hands, and soles of the feet, as well as oral, conjunctival, anogenital, and rectal mucosae. In a given anatomical region, lesions evolve synchronously through five sequential stages—macules → papules → vesicles → umbilicated pustules (deep-seated, firm, 2–10 mm) → crusts/scabs—before re-epithelializing and desquamating over 14 to 28 days. During the 2022–2026 Clade IIb and Clade Ib epidemics, direct mucosal inoculation during sexual contact frequently produced localized anogenital, perianal, or oropharyngeal ulcerations, severe proctitis, and tonsillitis that preceded or occurred without a generalized rash (Thornhill et al., 2022). Severe necrotizing skin lesions, ocular keratitis, encephalomyelitis, and pulmonary nodules occur predominantly in individuals with untreated HIV infection (CD4+ count < 200 cells/μL), young children, and pregnant women (where transplacental vertical transmission causes fetal demise).
Host APOBEC3 Cytidine Deaminase Editing
Whereas double-stranded DNA orthopoxviruses typically evolve slowly via high-fidelity E9L polymerase proofreading (~1 to 2 nucleotide substitutions per genome per year), phylogenomic sequencing of Clade IIb (lineage B.1) in 2022 and Clade Ib in 2023–2024 revealed a 6- to 12-fold evolutionary acceleration (~12–20 substitutions per year) dominated by 5′-TC → 5′-TT (and complementary 5′-GA → 5′-AA) dinucleotide transitions (Isidro et al., 2022; Vakaniaki et al., 2024). Over 85% of these mutations carry the exact sequence context signature of human APOBEC3 (apolipoprotein B mRNA-editing catalytic polypeptide-like 3, specifically APOBEC3F and APOBEC3G) cytidine deaminases, innate antiviral restriction enzymes that deaminate cytosine to uracil on transiently exposed single-stranded viral DNA replication intermediates—serving as a molecular clock of sustained human-to-human transmission.
Diagnostics, Cross-Protective Orthopoxvirus Vaccines, and Antivirals
Definitive diagnosis relies on real-time polymerase chain reaction (qPCR) amplification of conserved Orthopoxvirus (E9L, F3L) and Clade I/II-specific (G2R, C3L) targets from vigorous swabs of lesion exudate or crusts; note that the ~1.1 kbp C3L deletion in Clade Ib causes false-negative results on legacy Clade I-specific C3L assays unless pan-Orthopoxvirus or updated dual-target primers are used (Vakaniaki et al., 2024).
Because neutralizing antibodies against IMV (A27, L1, H3, D8) and EEV (B5, A33) surface proteins cross-react broadly across the genus Orthopoxvirus, immunization relies on third-generation vaccines:
- MVA-BN (Modified Vaccinia Ankara–Bavarian Nordic; Jynneos / Imvanex / Imvamune): A replication-deficient, live-attenuated vaccinia strain passaged >570 times in chick embryo fibroblasts, losing ~30 kbp of host-range DNA so it cannot replicate in mammalian cells. Administered as a two-dose subcutaneous regimen 28 days apart (or intradermally at one-fifth fractional volume during dose-sparing campaigns), two-dose MVA-BN achieves 66% to 86% real-world effectiveness against symptomatic mpox and is safe in immunocompromised hosts (Deputy et al., 2023).
- LC16m8: A minimally replicating attenuated Lister-strain vaccinia vaccine carrying a frameshift truncation in the EEV envelope gene B5R, licensed in Japan and deployed in pediatric outbreak responses in the DRC.
- Antiviral Therapeutics: Tecovirimat (TPOXX / ST-246) inhibits the conserved orthopoxvirus VP37 (F13L) palmitylated envelope phospholipase required for wrapping IMVs into EEVs, while brincidofovir (a lipid-conjugated nucleotide analog prodrug of cidofovir) inhibits the viral E9L DNA polymerase.
Recent Events
In 2022–2023, the global multi-country outbreak of monkeypox virus Clade IIb (lineage B.1) spread across more than 120 countries and caused over 100,000 laboratory-confirmed cases, prompting the World Health Organization to declare a Public Health Emergency of International Concern (PHEIC) from July 2022 to May 2023 while genomic sequencing revealed a 6- to 12-fold evolutionary acceleration driven by human APOBEC3 cytidine deaminase editing and real-world studies confirmed 66% to 86% two-dose MVA-BN (Jynneos) vaccine effectiveness [1] [2] [4].
In 2023–2024, a genetically distinct lineage designated Clade Ib emerged in the mining town of Kamituga in South Kivu Province, Democratic Republic of the Congo, carrying APOBEC3-mediated cytosine deamination signatures of sustained human-to-human transmission alongside a diagnostic ~1,142-bp deletion spanning the OPG032 (C3L complement-control protein) locus that caused target failure on standard Clade I PCR assays [5] [6].
In 2024–2026, rapid heterosexual and household spread of Clade Ib across eastern DRC and into Burundi, Uganda, Rwanda, and Kenya—co-circulating with endemic Clade Ia in central DRC—prompted the WHO to declare a second PHEIC on August 14, 2024 and prequalify MVA-BN and authorize LC16m8 for African outbreak response, while randomized clinical trials (PALM 007 for Clade I in DRC and STOMP for Clade II) reported that oral tecovirimat did not reduce the time to lesion resolution compared with supportive care [6] [7] [8].
Frequently Asked Questions
Why is monkeypox virus (MPXV) able to replicate in the cytoplasm when almost all other DNA viruses must enter the host cell nucleus?
Most DNA viruses (such as herpesviruses, adenoviruses, and papillomaviruses) rely on the host cell's nuclear RNA Polymerase II and DNA replication enzymes, requiring their genomes to enter the nucleus. Poxviruses like MPXV carry a large ~197 kbp genome that encodes a complete, self-contained cytoplasmic transcription and replication apparatus—including a viral multi-subunit DNA-dependent RNA polymerase, mRNA capping and polyadenylation enzymes, and the E9L DNA polymerase—packaged directly inside the infectious virion core so transcription begins in the cytoplasm minutes after entry.
What do APOBEC3 mutations reveal about how mpox spreads?
APOBEC3F and APOBEC3G are human intracellular innate immune enzymes that attack single-stranded viral DNA intermediates by deaminating cytosine (C) into uracil (U), resulting in characteristic 5′-TC → 5′-TT (and 5′-GA → 5′-AA) mutations in progeny viral genomes. When MPXV circulates in rodent reservoirs, it accumulates only 1 to 2 random substitutions per year; when it jumps into sustained human-to-human transmission chains (as in Clade IIb since ~2016 and Clade Ib since 2023), human APOBEC3 editing leaves a dense cluster of TC→TT transitions (~12–20 per year) that allows genomic epidemiologists to date when sustained human transmission began.
Why did smallpox vaccines protect against mpox, and why did mpox cases rise over the past forty years?
All members of the genus Orthopoxvirus—including variola virus (smallpox), vaccinia virus (used in smallpox vaccines), and monkeypox virus—share >90% amino acid identity across their core surface envelope antigens (A27, L1, D8, H3, B5, A33). Following the global certification of smallpox eradication in 1980, routine childhood vaccinia immunization ended worldwide; over the ensuing four decades, the proportion of the global population with cross-protective Orthopoxvirus immunity declined from >80% to <20%, expanding the susceptible human cohort in both endemic African regions and global urban networks.
References
- Isidro, J., Borges, V., Pinto, M., Sobral, D., Santos, J. D., Nunes, A., Mixão, V., Ferreira, R., Santos, D., Duarte, S., Vieira, L., Borrego, M. J., Núncio, S., de Carvalho, I. L., Pelerito, A., Cordeiro, R., & Gomes, J. P. (2022). Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nature Medicine, 28(8), 1569–1572. https://doi.org/10.1038/s41591-022-01907-y
- Thornhill, J. P., Barkati, S., Walmsley, S., Rockstroh, J., Antinori, A., Harrison, L. B., Palich, R., Nori, A., Reeves, I., Habibi, M. S., Apea, V., Boesecke, C., Vandekerckhove, L., Yakubovsky, M., Sendagorta, E., Blanco, J. L., Godineau, E., ... Orkin, C. M. (2022). Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022. New England Journal of Medicine, 387(8), 679–691. https://doi.org/10.1056/NEJMoa2207323
- Gessain, A., Nakoune, E., & Yazdanpanah, Y. (2022). Monkeypox. New England Journal of Medicine, 387(19), 1783–1793. https://doi.org/10.1056/NEJMra2208860
- Deputy, N. P., Deckert, J., Chard, A. N., Sandberg, N., Moulia, D. L., Barkley, E., Dalton, A. F., Sweet, C., Cohn, A. C., Little, D. R., Cohen, A. L., Sandmann, D., Payne, D. C., Gerhart, J. L., & Feldstein, L. R. (2023). Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States. New England Journal of Medicine, 388(26), 2434–2443. https://doi.org/10.1056/NEJMoa2215201
- O'Toole, Á., Neher, R. A., Ndodo, N., Borges, V., Gannon, B., Gomes, J. P., Groves, N., King, D. J., Maloney, D., Lemey, P., ... & Rambaut, A. (2023). APOBEC3 deaminase editing in mpox virus as evidence for sustained human transmission since at least 2016. Science, 382(6670), 595–600. https://doi.org/10.1126/science.adg8116
- Vakaniaki, E. H., Kacita, C., Kinganda-Lusamaki, E., O'Toole, Á., Wawina-Bokalanga, T., Mukadi-Bamuleka, D., Amuri-Aziza, A., Malyamungu-Bubala, N., Mweshi-Kumbana, F., Mutimbwa-Mambo, L., Belesi-Siangoli, F., Mujula, Y., Parker, E., Muswamba-Kayembe, P.-C., Nundu, S. S., Lushima, R. S., ... Mbala-Kingebeni, P. (2024). Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nature Medicine, 30(10), 2791–2795. https://doi.org/10.1038/s41591-024-03130-3
- The PALM007 Writing Group (2025). Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo. New England Journal of Medicine, 392(15), 1484–1496. https://doi.org/10.1056/NEJMoa2412439
- Zucker, J., Fischer, W. A. 2nd, Zheng, L., et al. (2026). Tecovirimat for the Treatment of Mpox. New England Journal of Medicine, 394(9), 884–895. https://doi.org/10.1056/NEJMoa2506495